Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

Studied

Phase 3 randomized trial comparing semaglutide with placebo for metabolic fatty liver inflammation and scarring.

Who / model

The reported analysis included 800 patients with biopsy-confirmed liver inflammation and fibrosis stage 2 or 3, assessed at 72 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both primary outcomes favored semaglutide: inflammation resolved without worse scarring in 62.9% versus 34.3%; scarring improved without worse inflammation in 36.8% versus 22.4%. Secondary results showed both improvements together in 32.7% versus 16.1%, and weight loss of 10.5% versus 2.0%. Pain scores did not clearly differ. Digestive adverse events were more common.

Limits

This was a planned interim analysis of the first 800 participants in an ongoing 1197-patient trial planned for 240 weeks.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary